TechTarget, Tower Bancorp and Citi Trends lead small-cap percentage losers
Also included among the results: Cardiovascular Systems Inc. (Nasdaq:CSII), Medicinova Inc. (Nasdaq:MNOV), C&F Financial Corp. (Nasdaq:CFFI), Williams Controls Inc. (Nasdaq:WMCO), Cyberonics Inc. (Nasdaq:CYBX) and BankAtlantic Bancorp Inc. (Nasdaq:BBX).
Celera, iRobot and NetGear lead small-cap percentage losers
Also included among the results: American River Bankshares (Nasdaq:AMRB), Medicinova Inc. (Nasdaq:MNOV), Vasco Data Security International Inc. (Nasdaq:VDSI), MasTec Inc. (Nasdaq:MTZ), Whitney Holding Corp. (Nasdaq:WTNY) and Northeast Community Bancorp Inc. (Nasdaq:NECB).
Medicinova, Biocryst Pharmaceuticals and JDA Software Group among 52-week highs
Also included among the results: Lannett Co Inc. (Nasdaq:LCI), RINO International Corp. (Nasdaq:RINO), Dorman Products Inc. (Nasdaq:DORM), Intellon Corp. (Nasdaq:ITLN), Fuqi International Inc. (Nasdaq:FUQI) and NeurogesX Inc. (Nasdaq:NGSX).
JDA Software Group, Medicinova and Biocryst Pharmaceuticals lead small-cap percentage gainers
Also included among the results: WNS Holdings Ltd. (Nasdaq:WNS), Amerigon Inc.(Nasdaq:ARGN), IncrediMail Ltd. (Nasdaq:MAIL), Hawk Corp. (Nasdaq:HWK), Protalix BioTherapeutics Inc. (Nasdaq:PLX) and Spectrum Pharmaceuticals Inc. (Nasdaq:SPPI).
CNinsure, Medicinova and Sharps Compliance among 52-week highs
Also included among the results: Amcon Distributing Co. (Nasdaq:DIT), Destination Maternity Corp. (Nasdaq:DEST), Young Innovations Inc. (Nasdaq:YDNT), Medifast Inc. (Nasdaq:MED), Universal Forest Products Inc. (Nasdaq:UFPI) and Health Fitness Corp. (Nasdaq:FIT).
Sturm, Ruger & Co., Triad Guaranty and Barrett Business Services lead small-cap percentage losers
Sturm, Ruger & Co. (NYSE: RGR), Triad Guaranty Inc. (Nasdaq: TGIC) and Barrett Business Services, Inc. (Nasdaq: BBSI) are among the biggest percentage losers in Thursday's trading among companies with market capitalizations under $750 million.
Here are today's biggest percentage losers:
MediciNova's clinical trial for insomnia fails
Shares of MediciNova, Inc. (Nasdaq: MNOV) are sagging this morning in pre-market trading after the a biopharmaceutical company said that its Phase IIa trial for the treatment of insomnia failed.
Shares of MediciNova (MNOV) slipped 9.4%, or $0.70, to $6.75 in pre-market trading. Shares of MediciNova have been trading in the range of $6.35 to $16.12 for the 52 weeks.


















